santosh006

SUBMITTED BY: santosh006

DATE: July 19, 2022, 11:26 a.m.

FORMAT: Text only

SIZE: 5.1 kB

Raw Download

HITS: 324

Report
  1. Gastrointestinal Drugs Market to Develop Rapidly by 2027
  3. According to our new market research study on “Gastrointestinal Drugs Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug Class, Route of Administration, Application, and Distribution Channel,” the market is expected to reach US$ 71,300.28 million in 2027 from US$ 49,043.38 million in 2019. The market is estimated to grow at a CAGR of 4.9% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
  5. Based on drug class, the market is segmented in to acid neutralizers, antidiarrheal and laxatives, anti-inflammatory drugs, antiemetic and antinauseants, biologics, and others.
  7. In 2019, the acid neutralizers segment held the largest share of the market. The biologics segment is expected to grow at the fastest CAGR during the forecast period. The advent of biologics has had a significant impact on the management of inflammatory bowel disease (IBD). Treatment with biologics has led to an improved quality of life for patients living with Crohn's disease and ulcerative colitis, with fewer admissions to the hospital and less side effects from corticosteroids. These are the most recently developed treatments for IBD. Biologic therapies are indicated for people with moderately to severely active disease who have not responded well to conventional therapy. Four of these agents (adalimumab, certolizumab pegol, golimumab and infliximab) target an inflammatory protein called tumor necrosis factor (TNF). Natalizumab and vedolizumab work by blocking certain types of white blood cells from getting into inflamed tissues.
  9. Biologics are beneficial for patients with gastrointestinal disorders who are not responding to conventional treatment. For instance, infliximab, which is derived from monoclonal antibodies to tumor necrosis factor is another modifier of the immune system's actions. Infliximab is given as a series of infusions by vein. This drug can be given to treat moderate to severe Crohn’s disease that has not responded to other drugs, to treat people with fistulas, and to maintain response when the disease is difficult to control. Vedolizumab and natalizumab are drugs for people who have moderate to severe Crohn’s disease that have not responded to TNF inhibitors or other immunomodulating drugs. With the increasing number of biologics in pipeline, the segment is expected to grow at a rapid pace during the forecast period. For instance, Takeda Pharmaceutical Company Limited has five candidates in different phases for various GI indications.
  11. Sanofi; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Bausch Health; AstraZeneca; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Bayer AG; Celltrion Healthcare Co., Ltd; and LEXICON PHARMACEUTICALS, INC. are among the leading companies operating in the gastrointestinal drugs market.
  13. Get Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00014758/
  15. The report segments global gastrointestinal drugs market as follows:
  19. By Drug Class
  21. Acid Neutralizers
  22. Antidiarrheal and Laxatives
  23. Anti-Inflammatory Drugs
  24. Antiemetic and Antinauseants
  25. Biologics
  26. Others
  27. By Route of Administration
  29. Oral
  30. Parenteral
  31. By Application
  33. Inflammatory Ulcerative Colitis
  34. Crohn's Disease
  35. Irritable Bowel Syndrome
  36. Gastroenteritis
  37. Celiac Disease
  38. Others
  39. By Distribution Channel
  41. Hospital Pharmacies
  42. Retail Pharmacies
  43. Online Pharmacies
  44. By Geography
  46. North America
  47. US
  48. Canada
  49. Mexico
  50. Europe
  51. France
  52. Germany
  53. UK
  54. Spain
  55. Italy
  56. Rest of Europe
  57. Asia Pacific (APAC)
  58. China
  59. India
  60. Japan
  61. Australia
  62. South Korea
  63. Rest of APAC
  64. Middle East & Africa (MEA)
  65. Saudi Arabia
  66. UAE
  67. South Africa
  68. Rest of MEA
  69. South and Central America (SCAM)
  70. Brazil
  71. Argentina
  72. Rest of SCAM
  73. Buy Now: https://www.theinsightpartners.com/buy/TIPRE00014758/
  75. Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, Others); Route of Administration (Oral, Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography
  77. About Us:
  79. The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
  81. Contact Us:
  83. If you have any queries about this report or if you would like further information, please contact us:
  85. Contact Person: Sameer Joshi
  87. E-mail: sales@theinsightpartners.com
  89. Phone: +1-646-491-9876
comments powered by Disqus